This Fact-Checking Charter and Non-Advisory Legal Notice sets forth the standards of factual verification, analytical limitations, and legal boundaries governing all content published by IXFY. Readers are advised to review these provisions carefully.

1. Independent Journalistic & Educational Purpose

IXFY is an independent digital news and intelligence publishing platform. All content available on this website—including news articles, investigative features, market commentary, sectoral analyses, graphical visualizations, and executive interviews—is published solely for informational, journalistic, and educational purposes.

Nothing published on IXFY constitutes, or is intended to constitute, an endorsement, solicitation, sponsorship, or recommendation of any security, corporate entity, investment strategy, medical treatment, or commercial product.

2. Non-Advisory Nature (Financial, Investment & Securities)

IXFY is not a registered investment advisor, broker-dealer, commodity trading advisor, or financial planning firm.

  • No Financial Advice: Content on this platform does not constitute personal financial advice, investment analysis, or a portfolio recommendation tailored to any individual's financial situation, risk profile, or investment objectives.
  • Capital at Risk: Investments in equities, venture capital, early-stage biotechnology, artificial intelligence startups, and commodities carry high degrees of financial risk, including the possible loss of principal capital. Past performance is no guarantee of future results.
  • Consult Certified Professionals: Readers must not make investment, trading, or capital allocation decisions based solely on information found on this site. You must consult a licensed financial advisor, certified accountant, or wealth manager before executing any financial transaction.

3. Non-Advisory Nature (Medical, Health & Biotechnology)

IXFY reporting on biotechnology, clinical trials, oncology, pharmaceuticals, and diagnostics is strictly journalistic in scope.

  • Not Clinical Advice: Articles describing experimental therapies, molecular compounds, clinical trials, or medical devices are provided for scientific intelligence and business reporting purposes only.
  • No Diagnostic Guidance: Content must never be used to diagnose, treat, cure, or prevent any illness or health condition. Readers must consult qualified healthcare practitioners, physicians, and medical authorities for clinical decisions.

4. Market Data, Valuations & Real-Time Indicators

Market indices, stock quotes, corporate valuation figures, funding totals, and billionaire net worth estimates presented on IXFY are derived from public regulatory disclosures, press announcements, and reputable market data feeds:

  • Latency and Fluctuations: Numerical metrics may be delayed, rounded, or subject to intra-day market volatility. IXFY does not guarantee that market figures are real-time, error-free, or continuously updated.
  • Third-Party Integrity: While metrics are compiled from sources believed to be reliable, IXFY makes no warranty regarding the completeness, timeliness, or mathematical precision of third-party data feeds.

5. Forward-Looking Statements & Safe Harbor Disclosures

Articles published on IXFY frequently discuss emerging technologies, planned corporate expansions, pipeline clinical readouts, regulatory filings, and future revenue projections.

These statements constitute forward-looking statements that are inherently subject to technological hurdles, clinical trial failures, regulatory denials, macroeconomic volatility, and competitive disruptions. Actual corporate outcomes may differ materially from those projected. IXFY assumes no obligation to publicly revise or update forward-looking statements outside our routine news reporting cycle.

6. Mandatory Independent Due Diligence

Readers, institutional researchers, and corporate executives are solely responsible for conducting their own independent due diligence, auditing primary documents, and verifying regulatory status prior to undertaking contractual or financial commitments.

7. Third-Party Hyperlinks & External References

IXFY articles may contain links to external web resources, academic databases, patent registers, and government websites. These links are provided solely for reader reference and verification convenience. IXFY exercises no operational control over external websites, does not endorse third-party content, and accepts no liability for third-party privacy practices or commercial terms.

8. Limitation of Liability

To the maximum extent permitted by applicable law, IXFY Media Group, its publishers, directors, editorial staff, and contributors shall not be liable for any direct, indirect, incidental, consequential, special, or punitive damages arising from the use of, or inability to use, information, data, or commentary published on this platform.